GLP-1 agonists: Diabetes drugs and weight loss - Mayo Clinic
Oct 29, 2024 · Studies have found that GLP-1 drugs can lead to weight loss of about 10.5 to 15.8 pounds (4.8 to 7.2 kilograms, or kg). Studies found people using semaglutide and making lifestyle changes lost about 33.7 pounds (15.3 kilograms) versus 5.7 pounds (2.6 kilograms) in those who didn't use the drug. Diabetes drugs in the GLP-1 agonists class are ...
Semaglutide (subcutaneous route) - Mayo Clinic
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Semaglutide injection is also used together with diet and exercise to help lose weight and keep the weight off in patients with at least one weight-related medical condition.
Agonistas del GLP-1: fármacos para la diabetes y pérdida de peso
Aug 11, 2022 · Una segunda clase de medicamentos que pueden ayudar a bajar de peso y mejorar el control de la glucosa en la sangre son los inhibidores del cotrasportador de sodio-glucosa tipo 2. Entre estos, se encuentran la canagliflozina (Invokana), la ertugliflozina (Steglatro), la dapagliflozina (Farxiga) y la empagliflozina (Jardiance).
Tirzepatide (subcutaneous route) - Mayo Clinic
Feb 1, 2024 · Description. Tirzepatide injection is used to treat type 2 diabetes. It is used together with diet and exercise to help control your blood sugar. Tirzapatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist. Tirzepatide injection is also used to help lose weight and keep the ...
Semaglutide (oral route) - Mayo Clinic
Feb 1, 2024 · Semaglutide is used to treat type 2 diabetes. It is used together with diet and exercise to help control your blood sugar. This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist. This medicine is available only with your doctor's prescription. This product is available in the following dosage forms:
Liraglutide (subcutaneous route) - Mayo Clinic
Liraglutide injection is used with diet and exercise to lower blood sugar in people with type 2 diabetes. It is also used to reduce the risk of life-threatening events, including heart attack and stroke, in adults with type 2 diabetes and established heart or blood vessel disease. This medicine is a glucagon-like peptide-1 (GLP-1) receptor agonist.
ناهضات GLP-1: عقاقير مرض السكري وفقدان الوزن - Mayo Clinic (مايو كلينك)
ويُطلق على هذه الفئة من الأدوية عادةً ناهضات الببتيد المشابه للغلوكاجون 1 (GLP-1). كذلك تتوفر فئة أخرى من الأدوية قد تساعد في تخفيف الوزن وتحسين التحكم في نسبة السكر في الدم، وهي مثبطات الناقل ...
GLP-1 激动剂：糖尿病药物和减重 - 妙佑医疗国际
Dec 15, 2022 · 研究表明，所有 GLP-1 药物都有利于减重，其中利拉鲁肽能使体重减轻大约 4.8 - 7.2 公斤（约 10.5 - 15.8 磅）。. 研究发现，服用司美格鲁肽并改变生活方式的人减掉了大约 15.3 公斤（33.7 磅），而没有服用该药物的人减掉了 2.6 公斤（5.7 磅）。. GLP-1 激动剂类糖尿病 ...
Management of obesity within hepatology clinics - Mayo Clinic
Dec 12, 2023 · Glucagon-like peptide 1 (GLP-1) receptor agonists. These agents can lead to significant weight loss. According to Dr. Watt, developing a solid understanding of how the various GLP-1 receptor agonists differ from one another may help clinicians choose the most appropriate agent for an individual patient. The Hepatology article contains a ...
Losartan (oral route) - Mayo Clinic
Losartan is an angiotensin II receptor blocker (ARB). It works by blocking a substance in the body that causes blood vessels to tighten. As a result, losartan relaxes the blood vessels. A lower blood pressure will increase the supply of the blood and oxygen to the heart.